Skip to main content

Advertisement

Table 3 CERTAIN patients not included in the primary analysis population because they had not previously received anti-TNF therapy at the time of initiation of a new biologic

From: Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients

  All Anti-TNF agents initiators Non-anti-TNF agents initiators Standardized absolute mean difference
Total, n 913 762 151  
Age (median, IQR), years 56 [48,65] 55 [47,64] 60 [51,69] 0.349
Female, n (%) 675 (77.2) 563 (76.9) 112 (78.9) 0.047
Caucasian, n (%) 708 (80.8) 596 (81.2) 112 (78.9) 0.058
RA disease duration (median, IQR), years 2 [1,7] 2 [1,6] 4 [1,11] 0.294
CDAI (median, IQR) 27 [20,37] 26 [20,36] 28 [20,38] 0.115
DAS28-CRP (median, IQR) 4.8 [4.1,5.5] 4.9 [4.1,5.5] 4.6 [3.9,5.4] 0.114
Biologic Monotherapy, n (%) 221 (24.2) 178 (23.4) 43 (28.5) 0.117
Concurrent DMARDs, n (%) 692 (75.8) 584 (76.6) 108 (71.5) 0.117
  MTX only, n (%) 486 (53.2) 425 (55.8) 61 (40.4) 0.311
  MTX dose (med, IQR) mg/week 20 [15,20] 20 [15,20] 20 [15,20] 0.149
  MTX plus other DMARDs, n (%) 95 (10.4) 81 (10.6) 14 (9.3) 0.045
  Leflunomide only, n (%) 39 (4.3) 29 (3.8) 10 (6.6) 0.127
  Sulfasalazine only, n (%) 13 (1.4) 10 (1.3) 3 (2) 0.053
  Hydroxychloroquine only, n (%) 33 (3.6) 27 (3.5) 6 (4) 0.023
Concomitant prednisone, n (%) 287 (31.4) 243 (31.9) 44 (29.1) 0.060
  Prednisone dose (median, IQR) mg 5 [5,10] 5 [5,10] 5 [5,6] 0.256
  No use, n (%) 636 (69.7) 528 (69.3) 108 (71.5) 0.049
  Prednisone <5 mg, n (%) 37 (4.1) 27 (3.5) 10 (6.6) 0.140
  Prednisone 5- <10 mg, n (%) 134 (14.7) 111 (14.6) 23 (15.2) 0.019
  Prednisone ≥ 10 mg, n (%) 106 (11.6) 96 (12.6) 10 (6.6) 0.203
Number of prior biologics exposed to (median, IQR) 0 [0,0] 0 [0,0] 0 [0,0] 0.425
Number of prior non-biologic DMARDs exposed to (median, IQR) 1 [1,2] 1 [1,2] 2 [1,2] 0.343
Biologic started at enrollment, n (%)     
  Adalimumab 268 (29.4) 268 (35.2) N/A N/A
  Infliximab 180 (19.7) 180 (23.6) N/A N/A
  Etanercept 205 (22.5) 205 (26.9) N/A N/A
  Golimumab 20 (2.2) 20 (2.6) N/A N/A
  Certolizumab pegol 89 (9.7) 89 (11.7) N/A N/A
  Rituximab 15 (1.6) N/A 15 (9.9) N/A
  Abatacept 100 (11) N/A 100 (66.2) N/A
  Tocilizumab 36 (3.9) N/A 36 (23.8) N/A
Co-morbidities, n (%)     
  History of Cardiovascular disease* 71 (7.8) 54 (7.1) 17 (11.3) 0.145
  History of Hypertension 203 (28.2) 165 (26.9) 38 (35.8) 0.194
  History of Diabetes Mellitus 63 (9) 52 (8.7) 11 (11.2) 0.085
  Hyperlipidemia (Defined as: Total cholesterol > 240 mg/dL at baseline visit) 111 (13.5) 92 (13.3) 19 (14.2) 0.025
  History of Malignancy (includes non -melanoma skin cancers) 54 (5.9) 45 (5.9) 9 (6) 0.002
  1. Abbreviations: IQR interquartile range, CDAI clinical disease activity index, DAS28_CRP disease activity score with 28 joint counts and CRP (C- reactive protein) as the inflammatory marker.
  2. *History of cardiovascular disease included: cardiac revascularization procedures, ventricular arrhythmias, cardiac arrests, myocardial infarctions, acute coronary syndromes, unstable angina, coronary artery disease, congestive heart failure, stroke, transient ischemic attacks.
  3. (Data for patients enrolled as of October 7th 2013).